This technology is a mesh scaffold capable of growing probiotic strains against respiratory pathogens that can be used for the prevention and treatment of Chronic Obstructive Pulmonary Disease (COPD).
COPD is a chronic inflammatory respiratory disease characterized by obstructed airflow. Current treatments for COPD include bronchodilators and inhaled corticosteroids, which provide only symptomatic relief and do not address underlying disease progression markers such as chronic tissue inflammation, fibrosis, and respiratory infections. As such, there exists a need for a treatment to slow down or halt the progression of COPD, rather than alleviating symptoms.
This technology is a scaffold matrix capable of carrying probiotic strains which are active against respiratory pathogens. The bacteria are isolated from tablets, seeded onto mechanically robust electrospun scaffolds, and grown into colonies by incorporating nutrients, adjuvants, and other drugs and agents. This technology is then intended to be delivered orally, as a targeted prevention and treatment of respiratory diseases.
This technology has been validated in probiotics with an optimal culture period of 24 hours.
Patent Pending
IR CU23062
Licensing Contact: Joan Martinez
